MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Gian Paolo Tonini(Città della Speranza Foundation), Bruno De Bernardi(Istituto Giannina Gaslini), Achille Iolascon(Ceinge Biotecnologie Avanzate (Italy)), Paolo Bruzzi(Alleanza Contro il Cancro), Katia Mazzocco(Istituto Giannina Gaslini), Giuseppe Basso(University of Padua), Claudia Milanaccio(Istituto Giannina Gaslini), Patrizia Perri(Istituto Giannina Gaslini), Massimo Conte(Istituto Giannina Gaslini), Andrea Pession(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Paola Scaruffi(Azienda Ospedaliera S.Maria), Luca Boni(Ospedale Policlinico San Martino), Luca Cordero di Montezemolo(Istituto Giannina Gaslini), Crocifissa Lo Cunsolo(Istituto Giannina Gaslini), Nicola Marchese(University of Turin), Donald E. Rogers(Istituto Giannina Gaslini), Fiorina Casale(University of Naples Federico II)
Cited by 113
Related Papers
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
|Journal of Clinical Oncology|1993|2.3k
The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells
|Cell|2011|1.4k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k